Memphasys Raises $1.2M to Accelerate Felix™ Commercial Rollout

Capital Raise Fuels Felix™ Commercial Momentum

Memphasys Limited (ASX:MEM) has completed a $1.2 million placement at $0.005 per share, matching its recent trading price and volume-weighted averages. The raise attracted strong support from both new and existing sophisticated investors, signalling confidence in the company’s flagship Felix™ sperm separation system as it transitions from commercial validation to scaled execution.

The funds will primarily back manufacturing inventory build and the expansion of direct sales channels to meet increasing global demand. This injection comes on the heels of a landmark 12-month exclusive supply agreement with Monash IVF Group, marking Memphasys’ largest annual contract and first major foothold in its home Australian market.

International Contracts Drive Revenue Visibility

Memphasys has locked in over A$2.5 million in minimum contracted revenues across five international partnerships, underpinning a growing recurring revenue base. Key agreements include a five-year supply deal with CFA Italia valued at approximately A$925,000, an exclusive multi-year distribution partnership with ITL covering 353 clinics across the Middle East and North Africa, and a direct supply arrangement with Andrology Center/Andro Diagnostics reaching over 200 IVF clinics in India.

Additional contracts extend to Southeast Asia with a $530,000 deal in Vietnam and ongoing traction in Japan through Nishitan ART Clinic Group. These multi-year deals provide a foundation for predictable revenue streams and validate Felix™’s market potential beyond Australia.

Convertible Note Extension Enhances Financial Flexibility

Complementing the capital raise, Memphasys has extended the maturity of its convertible note with Peters Investments Pty Ltd by 12 months to June 30, 2027. The amendment preserves all existing terms, including interest rate and conversion rights, providing the company with additional runway to execute its commercialisation strategy without altering its debt profile.

Chair David Tasker highlighted the extension as a crucial element of balance sheet stability, enabling Memphasys to capitalise on its expanding contracted revenues and the momentum from its Monash IVF partnership. Peters Investments’ longstanding support is presented as a strong endorsement of the company’s strategic direction.

Scaling Production to Meet Growing Demand

With the capital raise and convertible note extension in place, Memphasys is positioned to ramp up production of Felix™ cartridges, the consumable component driving recurring revenue. The company’s commercial strategy hinges on building contracted sales through a mix of direct and distribution-led channels while improving manufacturing scale and margins.

As Felix™ replaces traditional sperm preparation methods with a patented, gentler technology, Memphasys aims to establish it as a global standard in assisted reproductive technology. The recent commercial contracts across diverse regions underscore growing acceptance and adoption of the system.